

1. [Who Does Most Harm To Global Innovation? India, China And Thailand](#) – Forbes

Finland, Sweden and the United Kingdom have done the most for global innovation on a per-capita basis while India, Indonesia, and Argentina have done the least, according to a [new report](#) by the Information Technology and Innovation Foundation, a Washington, D.C. think-tank that focuses on a range of issues at the intersection of technological innovation and public policy.

Innovation is the creation of new value for the world whether through new technologies, new business models, new products and services, or new forms of social entrepreneurship. As countries increasingly vie for leadership in the global

innovation economy, they can implement policies that benefit only themselves at the cost of hurting global innovation, or policies that can bolster their own innovation capacity while also generating positive spillovers that benefit the entire global innovation system, the report said.

2. [FDA finds Indian drug maker Wockhardt hid failed tests](#) – Reuters

Indian drugmaker Wockhardt hid the results of failed tests and deleted data from its systems at a plant in western India, according to a report by the U.S. Food and Drug Administration sent to the company earlier this month and seen by Reuters.

Issues around "data integrity", maintaining accurate and consistent databases, are key to the U.S. watchdog, which regulates the world's largest market for generics producers.

3. [Roche expects cancer treatments to be spared U.S. pricing curbs](#) – Reuters

The U.S. Congress may intervene on how much companies can charge for some drugs following a move last year by Turing Pharmaceuticals to ratchet up the price of a treatment for deadly parasite infections by 5,000 percent, Roche's head of pharmaceuticals said.

1. [Who Does Most Harm To Global Innovation? India, China And Thailand](#) – Forbes
2. [FDA finds Indian drug maker Wockhardt hid failed tests](#) – Reuters
3. [Roche expects cancer treatments to be spared U.S. pricing curbs](#) – Reuters
4. [Sanofi aims for increased presence in Iran](#) – Reuters
5. [Cipla head moots new policies for critical drugs](#) – The Hindu Business Line
6. [EPharma discounts rage as govt carries on norms](#) – Hindustan Times
7. [After IT, healthcare can be the next sector where India dominates the world](#) – The Economic Times
8. [Onus on senior management of drugmakers to maintain quality, says FDA's report](#) – The Economic Times
9. [India's Pharmaceuticals Market Will Skyrocket from \\$20 Billion in 2015 to \\$55 Billion by 2020, says GlobalData](#) – ETHealth
10. ['Most Indian docs prefer digital interaction'](#) - ETHealth
11. [Industry expresses relief over DoP decision to set up separate ministry for pharma sector soon](#) – Pharmabiz.com

Roche's Dan O'Day is convinced the oncology portfolio at the world's biggest maker of cancer drugs will not be affected, arguing it offers innovative treatments for diseases with few other options.

4. [Sanofi aims for increased presence in Iran](#) – Reuters

Sanofi signed a memorandum of cooperation with Iran's government aimed at boosting its presence in the country, the French drugmaker said on Thursday.

The agreement was signed during the visit to Paris of President Hassan Rouhani during which France and Iran agreed to a series of transactions with several French firms.

Medicines were an exception in the nuclear sanctions imposed on Iran, thanks to exemptions for essential drugs and other humanitarian goods. Yet shipping drugs into the country was still difficult.

5. [Cipla head moots new policies for critical drugs](#) – The Hindu Business Line

The Centre needs to frame guidelines to facilitate licensing arrangements between companies to bring critical drugs into the country, according to Cipla Chairman Dr YK Hamied.

“We have to devise policies that secure people’s right to access affordable quality medicines without monopoly. A favourable and pragmatic licensing policy should be provided for drugs under monopoly,” he said in his acceptance speech after receiving the Lifetime Achievement Award from the Indian Drug Manufacturers’ Association (IDMA).

Stressing the need for companies to be able to partner with innovator companies, he said it is important that the latest therapies are available in our country. “If companies are unable to get licences for drugs under monopoly, the Government of India should intervene on behalf of the country for a non-exclusive compulsory licence with a fixed royalty to the innovator, so that patients are not denied life-saving

6. [EPharma discounts rage as govt tarries on norms](#) – Hindustan Times

The war to sell products online by luring consumer with discount coupons, cashbacks, recharge coupons and gift cards has found new sector: Pharmaceuticals.

While government is still drafting the guidelines to regulate the highly sensitive sector, ePharmacists are busy designing strategies to attract patients.

7. [After IT, healthcare can be the next sector where India dominates the world](#) – The Economic Times

Global healthcare and wellness is a \$7.4 trillion industry, second only to the food and agro industry. Who is going to dominate this industry?

The economy of the 20th century was driven by machines which replaced human toil. We, in India, missed that golden opportunity. But the economy of the 21st century will be driven by the health sector, which can be dominated by Indians. Indian doctors are known to be inherently compassionate and have magic in their fingers.

8. [Onus on senior management of drugmakers to maintain quality, says FDA's report](#) – The Economic Times

Indian drug companies battling the stringent rules of the US Food and Drug Administration might have to make additional commitment to prove that they are compliant with the good manufacturing guidelines of the regulator.

The USFDA has proposed a new system that will evaluate the health of the quality culture of drug companies.

In a draft report on quality metrics, the USFDA suggested various quantifiable parameters with an attempt to manage its inspection schedule and identify possible situations where there is a risk of drug shortage, among other issues. With that intention, the regulator wants to measure the commitment of senior management to quality.

9. [India's Pharmaceuticals Market Will Skyrocket from \\$20 Billion in 2015 to \\$55 Billion by 2020, says GlobalData](#) – ETHealth

The pharmaceuticals market in India, valued at \$20 billion in 2015, is set to soar to \$55 billion by 2020, representing an impressive Compound Annual Growth Rate (CAGR) of 22.4%, says research and consulting firm GlobalData.

According to the company's latest report\*, India's rapidly growing generics market is the primary driver of the nation's pharmaceutical sector, with sales expected to soar by nearly 84% to \$26.1 billion in 2016. Generic drugs, with their low costs and easy accessibility, now dominate India's pharmaceutical space, accounting for around 70% of the market.

10. ['Most Indian docs prefer digital interaction'](#) - ETHealth

Over 60% of doctors in the country now prefer, one out of three times, digital interaction with their patients as against the traditional face-to-face interaction, indicating a trend where WhatsApp, text messages and emails are increasingly being used for consultations. Also, a majority of doctors - globally 60% - demand drug companies combine the use of digital tablets and iPads along with direct interaction when medical representatives (MRs) are detailing the portfolio of medicines. This also works well with pharmaceutical companies in terms of costs, as well as adherence to ethical marketing code

11. [Industry expresses relief over DoP decision to set up separate ministry for pharma sector soon](#) – Pharmabiz.com

Welcoming the department of pharmaceuticals (DoP)'s strategic announcement to finally establish a separate ministry for the pharma sector soon, industry experts stressed that this much awaited news comes as a huge relief as it will finally ensure timely redressal of issues affected by different sectors. DoP recently had informed that they are in the final stages of setting up a separate ministry, to cater to the regulatory and other needs of the sectors like pharma, medical device, etc., on the lines of ministry of Ayush.

This much sought after announcement was made by the DoP during the recently concluded India Pharma and Indian Medical Expo 2016 in Bengaluru which was organised to woo investors and strategic collaborations by highlighting the strength of finished formulations, APIs, natural extracts, pharma machinery, medical devices and instruments. Industry insiders pointed out that they are eagerly waiting for this to operationalise as it will help in addressing their issues without the usual bureaucratic red tape.